Datavault AI Inc, a provider of data monetization, credentialing, digital engagement, and real-world asset (‘RWA’) tokenization technologies, announced that it has amended its definitive agreement with DataMeds AI, Inc. to expand its PharmacyChain blockchain-related technology licensing relationship beyond pharmaceutical distribution to include all unencumbered commercial healthcare, healthspan and wellness applications of Datavault AI’s intellectual property.
The behavioral healthcare patent portfolio being acquired was developed at La Frontera Arizona by the late Senator David T. Bradley and Dr. Dan Ranieri, and covers medical and pharmaceutical logistics, IoT population health, and remote patient monitoring with AI-driven behavioral health insights and interventions. DataMeds is acquiring the portfolio in concurrent transactions with EOS Technology Holdings and Scilex.
“Our business model depends on extracting greater value from the information we generate every day. Datavault AI’s platform gives us confidence that we can transform data into a strategic asset for our future customers, not just for operational insights, but as a foundation for future commercial opportunities and customer acquisition strategies. We see this as the key step in modernizing how organizations think about data ownership and monetization in healthcare,” said Gerald Commissiong, Interim Co-CEO of DataMEDS.
Nathaniel T. Bradley, CEO of Datavault AI, said, “Extending our data monetization and tokenization platform into commercial healthcare, healthspan and wellness is a natural next step for patient-controlled data. DataMEDS gives us a focused path to put that technology to work so individuals have a say over how their own medical information is transacted.”
Under the terms of the amended definitive agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS common stock upon closing of the previously disclosed related transactions with Scilex Holding Company, EOS Technology Holdings, Inc. and HealthBridge Advisors, LLC, instead of preferred shares. The amendment was made to issue common shares in place of preferred shares to optimize the transaction for tax purposes. The share issuance remains subject to satisfaction of the closing conditions, including the acquisition of two QOLPOM intellectual property portfolios from EOS Technology Holdings and the acquisition of a controlling interest in Tollo Health LLC from HighBridge Advisors. The value of the share issuance to Datavault AI is expected to be categorized as revenue upon the common share issuance.
DataMEDS, formerly Wellgistics Health, Inc., announced on July 21, 2026, that it had completed its corporate name change, and stated that trading on the Nasdaq Capital Market under the symbol ‘MEDS’ began on July 22, 2026. DataMEDS is issuing a dividend of 50 Dream Bowl Meme Coin tokens for each share of DataMEDS common stock owned as of the August 7, 2026 record date, that is subject to change at DataMEDS’ sole discretion.
The expanded relationship is intended to extend Datavault AI’s data monetization and real-world asset tokenization technologies into the DataMEDS healthcare data environment, supporting patient-controlled health data access and data-transaction models across pharmacy, medical, laboratory and wearables settings. This comes as healthcare data—already representing approximately 30% of the world’s data volume and growing at an estimated 36% annually—creates substantial opportunities for patient-controlled monetization and real-world asset tokenization within a global health and wellness market exceeding $7 trillion. The companies executed the amended agreement ahead of completing the remaining closing conditions in order to accelerate operational execution, including access to Datavault AI’s technology relationships.
